Increased mortality in chronic kidney disease: A call to action

被引:45
作者
Perazella, MA
Khan, S
机构
[1] Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA
[2] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
关键词
mortality; chronic kidney disease; cardiovascular disease; GFR; risk factors;
D O I
10.1097/00000441-200603000-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mortality rate among patients with chronic kidney disease is much higher than among those without. As glomerular filtration rate declines and patients approach end-stage renal disease, the mortality rate increases and patients at this stage are more likely to die than receive renal replacement therapy. The higher mortality and its underlying causes among chronic kidney disease patients is a serious issued Lack of physician awareness of chronic kidney disease and its association with excess mortality remains a problem. In this review of current literature, we aim to increase this awareness among health care professionals and the general public and to call for action to improve survival in chronic kidney disease patients. The data strongly suggest that advancing kidney dysfunction leads to increased mortality risk. Contributing to the mortality associated with chronic kidney disease are the comorbidities that accompany this disease state. For instance, patients with chronic kidney disease and comorbidities are at 1.3 to 3.6 times more risk than patients without chronic kidney disease. Further, cardiovascular disease is the leading cause of death among chronic kidney disease patients. It appears that both traditional (such as diabetes mellitus, hypertension, and smoking) and nontraditional risk factors (C-reactive protein and interleukin-6 levels) present in the chronic kidney disease population promote the frequent development of cardiovascular disease. Therefore, therapies targeting both progression of chronic kidney disease and comorbidities such as cardiovascular disease are required to reduce mortality among these patients.
引用
收藏
页码:150 / 153
页数:4
相关论文
共 14 条
[1]   Chronic kidney disease and cardiovascular disease in the Medicare population [J].
Collins, AJ ;
Li, SL ;
Gilbertson, DT ;
Liu, JN ;
Chen, SC ;
Herzog, CA .
KIDNEY INTERNATIONAL, 2003, 64 :S24-S31
[2]   Asymmetric dimethylarginine and progression of chronic kidney disease:: The mild to moderate kidney disease study [J].
Fliser, D ;
Kronenberg, F ;
Kielstein, JT ;
Morath, C ;
Bode-Böger, SM ;
Haller, H ;
Ritz, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (08) :2456-2461
[3]   Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999 [J].
Foley, RN ;
Murray, AM ;
Li, SL ;
Herzog, CA ;
McBean, AM ;
Eggers, PW ;
Collins, AJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (02) :489-495
[4]   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].
Go, AS ;
Chertow, GM ;
Fan, DJ ;
McCulloch, CE ;
Hsu, CY .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305
[5]  
GULLION CG, 2003, AM SOC NEPHR NOV 14
[6]   Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the medicare population [J].
Herzog, CA ;
Muster, HA ;
Li, SL ;
Collins, AJ .
JOURNAL OF CARDIAC FAILURE, 2004, 10 (06) :467-472
[7]   Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization [J].
Keith, DS ;
Nichols, GA ;
Gullion, CM ;
Brown, JB ;
Smith, DH .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (06) :659-663
[8]  
PERAZELLA MA, 2005, NEPHROLOGY 30 DAYS, P251
[9]   Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach [J].
Ravani, P ;
Tripepi, G ;
Malberti, F ;
Testa, S ;
Mallamaci, F ;
Zoccali, C .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (08) :2449-2455
[10]   Cardiovascular mortality risk in chronic kidney disease - Comparison of traditional and novel risk factors [J].
Shlipak, MG ;
Fried, LF ;
Cushman, M ;
Manolio, TA ;
Peterson, D ;
Stehman-Breen, C ;
Bleyer, A ;
Newman, A ;
Siscovick, D ;
Psaty, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (14) :1737-1745